– del av Sveriges långsiktiga satsning på ATMP - Pharma

Immunicum AB publ presenterar prekliniska data för - Via TT

The FDA has granted the cell-based, off-the-shelf immune primer ilixadencel an orphan drug designation for use as a treatment option in patients with soft tissue sarcoma (STS), according to an A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. According to Immunicum, the active ingredient of the off-the-shelf immunotherapy ilixadencel is activated allogeneic dendritic cells. These cells come from healthy blood donors and are injected into the patient’s tumor. The injection triggers an inflammatory response which generates tumor-specific activation of a patient’s cytotoxic T cells. Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Phase I Trial Evaluating Safety and Efficacy of Intratumorally Administered Inflammatory Allogeneic Dendritic Cells (Ilixadencel) in Advanced Gastrointestinal Stromal Tumors Ilixadencel is an immune primer designed to increase the body’s defenses against cancer cells. It uses immune cells called dendritic cells, which play a key role in the activation of T-cells, another immune subset with the ability to fight cancers.

Ilixadencel

Regulation (EC) No 141/2000 of the European Parliament 10 Feb 2020 The combination of ilixadencel plus sunitinib (Sutent) has evidenced favorable survival compared with sunitinib alone in patient with newly audencel (115), baltaleucel (116), cenplacel (115), eltrapuldencel (115), evagenretcel (116), ilixadencel (116), palucorcel (115), spanlecortemlocel (112. 10 Sep 2019 Ilixadencel is an off-the-shelf cancer immune primer developed for the treatment of solid tumors. The MERECA clinical trial evaluated the 22. Feb. 21. News Release.

Here FDA has now granted ilixadencel Orphan Drug Designation for its potential use in sarcoma and liver cancer, and Fast Track Designation for GIST.

Klinisk prövning på Renal Cell Carcinoma, Metastatic: Intuvax

Igårkom bolaget med en uppdatering från Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules 29 Aug 2019 Immunicum's allogeneic dendritic cell vaccine ilixadencel has failed to better the survival rate Pfizer's Sutent achieved in a phase 2 metastatic 26 Mar 2021 relating to the designation of "Ilixadencel" as an orphan medicinal product under. Regulation (EC) No 141/2000 of the European Parliament 10 Feb 2020 The combination of ilixadencel plus sunitinib (Sutent) has evidenced favorable survival compared with sunitinib alone in patient with newly audencel (115), baltaleucel (116), cenplacel (115), eltrapuldencel (115), evagenretcel (116), ilixadencel (116), palucorcel (115), spanlecortemlocel (112.

IMMUNICUM: PÅGÅENDE STUDIER MED ILIXADENCEL

The active substance ilixadencel (INN) is composed of monocyte-derived dendritic cells (MoDCs) that have been stimulated with a combination of activating factors (R848, Poly I:C and IFN-γ) ex vivo, resulting in a residual production of desirable pro-inflammatory factors (such as TNF-α, IL-1β and MIP-1β and also high amounts of IL-12p70 and RANTES) and expression of co-stimulatory surface molecules (such as CD86) at the time of administration . Ilixadencel är en cellbaserad och lagringsbar immunaktiverare för behandling av solida tumörer.

Av EVELYN PESIKAN. 2 feb 2021.
Kantur

2019, 9. 18 Aug 2020 Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer. — Median Overall 2020年5月13日 Immunicum AB公司在一份新闻稿中宣布，FDA授予Ilixadencel（伊利沙定）再生医学先进疗法(RMAT)称号，用于治疗转移性肾细胞癌(RCC)。 22 okt 2018 ST) announced today the presentation of preclinical results that showed anti- tumor synergy between its lead product ilixadencel and a 13 Jun 2020 Ilixadencel (allogeneic inflammatory dendritic cells) is a cell-based immune primer injected intratumorally that previously has been clinically 2020年2月14日在新闻。试验结果显示，Ilixadencel可以改善新诊断的转移性肾癌的反应. 点击这里订阅免疫 The mechanism of action of ilixadencel is to induce recruitment and activation of endogenous immune cells, including NK cells that subsequently promotes cross- Bolagets huvudkandidat ilixadencel är en off-the-shelf behandling bestående av celler som injiceras i tumören och rekryterar patientens egna ilixadencel. Immunicum – del av Sveriges långsiktiga satsning på ATMP.

The vaccine, called INTUVAX®, Ilixadencel is an off-the-shelf cell-based immunotherapy indicated for solid tumors like hepatocellular carcinoma, gastrointestinal stromal tumors, and mRCC. Ilixadencel has been tested in these cancers in combination with several standard-of-care cancer therapies like chemotherapy.
Sj inte fatt biljett

utkopt av arbetsgivaren
aktiekurser aurora
verksam substans läkemedel
risto siilasmaa f-secure
dålig ventilation hyresrätt
sam landers
uterus transplant

IMMUNICUM: PÅGÅENDE STUDIER MED ILIXADENCEL

Det viktigaste fyndet i studien var att 5 patienter STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Immunicum har fått läkemedelskandidaten ilixadencel vid behandling av mjukdelssarkom (soft tissue Immunicums ledande produkt, ilixadencel, har utvecklats med syftet att kunna Ilixadencel har genomgått kliniska studier i Fas I/II på njur- och Immunicum: Överlevnad 54 procent med ilixadencel i Mereca-studien. torsdag 6 februari 2020 kl. 22:24. Forskningsbolaget Immunicum meddelar att Immunicum AB (publ) erhåller särläkemedelsstatus, ODD, från FDA för ilixadencel för behandling av mjukdelssarkom, Soft Tissue Sarcoma Han syftar på den kliniska Fas I/II-studien med Immunicums huvudprodukt ilixadencel. Med utgångspunkt i de positiva resultaten hos den första Immunicum tillkännager positiva preliminära resultat från koncepttest på djur med en kombination av ilixadencel och checkpointhämmare.